157 related articles for article (PubMed ID: 31709853)
101. Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives.
Candelario N; Lu ML
Cancer Manag Res; 2016; 8():77-82. PubMed ID: 27382332
[TBL] [Abstract][Full Text] [Related]
102. Aprepitant quetiapine: a clinically significant drug interaction in a patient treated for head and neck cancer.
Verwimp-Hoeks MPA; van Herpen CML; Burger DM
Ann Oncol; 2012 Mar; 23(3):801-802. PubMed ID: 22219014
[No Abstract] [Full Text] [Related]
103. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
Robinson P; Coveñas R; Muñoz M
Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620
[TBL] [Abstract][Full Text] [Related]
104. Effect of aprepitant on kynurenine to tryptophan ratio in cART treated and cART naïve adults living with HIV.
Spitsin S; Pappa V; Kinder A; Evans DL; Rappaport J; Douglas SD
Medicine (Baltimore); 2021 Jun; 100(23):e25313. PubMed ID: 34114978
[TBL] [Abstract][Full Text] [Related]
105. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
Tsuda T; Kyomori C; Mizukami T; Taniyama T; Izawa N; Horie Y; Hirakawa M; Ogura T; Nakajima TE; Tsugawa K; Boku N
Mol Clin Oncol; 2016 Apr; 4(4):603-606. PubMed ID: 27073673
[TBL] [Abstract][Full Text] [Related]
106. 15-hydroxystearate micelles for the delivery of aprepitant: Preparation, characterization, pharmacokinetics and tissue distribution in mice.
Ge J; Wang M; Kong H; Liu H; Pan H
Pak J Pharm Sci; 2021 Mar; 34(2):635-639. PubMed ID: 34275840
[TBL] [Abstract][Full Text] [Related]
107. Effect of Selective 5-Hydroxytryptamine-3 Receptor and Neurokinin-1 Receptor Antagonists on Hemodynamic Changes and Arrhythmogenic Potential in Patients Receiving Chemotherapy: A Retrospective, Observational Study.
Bozbulut UB; Cengiz T; Özet A
J Clin Med; 2024 Feb; 13(3):. PubMed ID: 38337537
[No Abstract] [Full Text] [Related]
108. Safety of intravenous push thiamine administration at a tertiary academic medical center.
McLaughlin K; Joyal K; Lee S; Corrado M; Marquis K; Anger K; Szumita P
J Am Pharm Assoc (2003); 2020; 60(4):598-601. PubMed ID: 31932197
[TBL] [Abstract][Full Text] [Related]
109. Evaluation of the Safety of Intravenous Thiamine Administration in a Large Academic Medical Center.
Tjugum SL; Hedrick TL; Jean SJ; Heeney SA; Rohde KA; Campbell-Bright SL
J Pharm Pract; 2021 Jun; 34(3):397-402. PubMed ID: 31495250
[TBL] [Abstract][Full Text] [Related]
110. Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients.
Sato Y; Kondo M; Inagaki A; Komatsu H; Okada C; Naruse K; Sahashi T; Kuroda J; Ogura H; Uegaki S; Yoshida T; Mori Y; Sawada H; Watanabe S; Sugiura H; Endo Y; Yoshimoto N; Toyama T; Iida S; Yamada K; Kimura K; Wakita A
J Cancer; 2014; 5(5):390-7. PubMed ID: 24799957
[TBL] [Abstract][Full Text] [Related]
111. Safety of Intravenous Push Ertapenem Compared to Intravenous Piggyback at a Tertiary Academic Medical Center.
Corrado MJ; Riselli A; McLaughlin KC; Szumita PM; Anger KE
J Pharm Pract; 2023 Apr; 36(2):281-285. PubMed ID: 34384303
[No Abstract] [Full Text] [Related]
112. Ethanol Exposure During the Intravenous Administration of Chemotherapeutic Drugs: An Analysis of Clinical Practice and a Literature Review.
Hiver Q; Henry H; Vasseur M; Cuvelier E; Le Rhun É; Turpin A; Décaudin B; Odou P; Simon N
JCO Oncol Pract; 2022 May; 18(5):e710-e720. PubMed ID: 34990287
[TBL] [Abstract][Full Text] [Related]
113. New formulation, new drug? The importance of assessing the safety of new supportive care formulations in oncology.
Jordan K
Ann Oncol; 2018 Jul; 29(7):1494-1496. PubMed ID: 29790903
[No Abstract] [Full Text] [Related]
114. Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial.
Zhang Z; Yang Y; Lu P; Li X; Chang J; Zheng R; Zhou L; Chen S; Chen X; Ren B; Gu W; Jiang X; Peng J; Huang M; Feng G; Shen P; Zhang Q; Zhang B; Huang Y; He J; Chen Y; Cao J; Wang H; Li W; Wan H; Nan K; Liao Z; Zhang C; Lin Z; Zhong D; Xu Q; Liu H; Sun T; Deng Y; Zhang L
Ann Transl Med; 2020 Mar; 8(5):234. PubMed ID: 32309381
[TBL] [Abstract][Full Text] [Related]
115. Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant.
Tyler T; Schultz A; Venturini A; Giuliano C; Bernareggi A; Spezia R; Voisin D; Stella V
Clin Pharmacol Drug Dev; 2022 Dec; 11(12):1405-1418. PubMed ID: 36263927
[TBL] [Abstract][Full Text] [Related]
116. Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting.
Jin Z; Daksla N; Gan TJ
Drugs; 2021 Jul; 81(10):1171-1179. PubMed ID: 34106456
[TBL] [Abstract][Full Text] [Related]
117. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Navari RM
Expert Opin Drug Saf; 2020 Feb; 19(2):205-210. PubMed ID: 31709853
[No Abstract] [Full Text] [Related]
118. HTX-019 via 2-min injection or 30-min infusion in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2019 Mar; 15(8):865-874. PubMed ID: 30574797
[TBL] [Abstract][Full Text] [Related]
119. Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review.
Walton GD
Adv Ther; 2019 Mar; 36(3):662-669. PubMed ID: 30706408
[TBL] [Abstract][Full Text] [Related]
120. Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy.
Navari RM; Mosier MC
Onco Targets Ther; 2019; 12():3277-3284. PubMed ID: 31118678
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
